Drug discovery from natural sources

AAPS Journal

Volumn 8, Issue 2, 2006, Pages

  Chin, Young Won ^a   Balunas, Marcy J ^a,b   Chai, Hee Byung ^a   Kinghorn, A Douglas ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chemical diversity; Drug discovery; Marine organisms; Natural products; Terrestrial invertebrates; Terrestrial microorganisms; Terrestrial plants; Terrestrial vertebrates

Indexed keywords

AMRUBICIN; APOMORPHINE; ARTEETHER; CASED; COMBRETASTATIN A4 PHOSPHATE; DAIDZEIN; DAPTOMYCIN; EVEROLIMUS; GALANTAMINE; HOMOHARRINGTONINE; INGENOL; IPRATROPIUM BROMIDE; ISOFLAVONE DERIVATIVE; MICAFUNGIN; MIGLUSTAT; MYCOPHENOLIC ACID; NATURAL PRODUCT; NEW DRUG; NITISINONE; ORGANIC COMPOUND; PHENOXODIOL; PROTOPANAXADIOL; ROSUVASTATIN; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SPIRIVA HANDIHALER; TELITHROMYCIN; TERPENOID DERIVATIVE; TIGECYCLINE; TIOTROPIUM BROMIDE; TRIPTOLIDE; TRIPTOLIDE SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DESIGN; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INVERTEBRATE; MARINE ENVIRONMENT; METABOLITE; MICROORGANISM; PARKINSON DISEASE; PLANT; REVIEW; TYROSINEMIA; VERTEBRATE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BIOLOGICAL PRODUCTS; FUNGI; INVERTEBRATES; PENICILLINS; PHARMACEUTICAL PREPARATIONS; PHYTOTHERAPY; PLANTS; VERTEBRATES;

EID: 33646056420     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080228     Document Type: Review

References (126)

1. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep. 2000;17:215-234.
2. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003;66:1022-1037.
3. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005;4:206-220.
4. Paterson I, Anderson EA. The renaissance of natural products as drug candidates. Science. 2005;310:451-453.
5. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78:431-441.
6. Jones WP, Chin Y-W, Kinghorn AD. The role of pharmacognosy in modern medicine and pharmacy. Curr Drug Targets. 2006;7:247-264.
7. Drahl C, Cravatt BF, Sorensen EJ. Protein-reactive natural products. Angew Chem Int Ed Engl. 2005;44:5788-5809.
8. Grifo F, Newman D, Fairfield A, Bhattacharya B, Grupenhoff J. The origins of prescription drugs. In: Grifo F, Rosenthal J, eds. Biodiversity and Human Health. Washington, DC: Island Press; 1997:131-163.
9. Butler MS. The role of natural product chemistry in drug discovery. J Nat Prod. 2004;67:2141-2153.
10. Thayer A. Bristol-Myers to settle suits. Chem Eng News. 2003;81:6.
11. Oberlies NH, Kroll DJ. Camptothecin and taxol: historic achievements in natural products research. J Nat Prod. 2004;67:129-135.
12. Butler MS. Natural products to drugs: natural products derived compounds in clinical trials. Nat Prod Rep. 2005;22:162-195.
13. Dewick PM. Medicinal Natural Products: A Biosynthetic Approach. 2nd ed. Chichester, UK: John Wiley & Sons; 2002.
14. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001;109:69-75.
15. Kinghorn AD. The discovery of drugs from higher plants. In: Gullo VP, ed. The Discovery of Natural Products with Therapeutic Potential. Boston, MA: Butterworth-Heinemann; 1994:81-108.
16. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging. 2004;21:687-709.
17. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther. 2005;27:377-392.
18. Hall MG, Wilks WF, Provan WM, Eksborg S, Lumholtz B. Pharmacokinetics and pharmacodynamics of NTBC [2-(2-nitro-4-fluoromethyl-benzoyl)-1,3-cyclohexanedione] and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol. 2001;52:169-177.
19. Mitchell G, Bartlett DW, Fraser TEM, et al. Mesotrione: a new selective herbicide for use in maize. Pest Manag Sci. 2001;57:120-128.
20. Howes M-JR, Perry NSL, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res. 2003;17:1-18.
21. Heinrich M, Teoh HL. Galanthamine from snowdrop - the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol. 2004;92:147-162.
22. van Agtmael MA, Eggelte TA, van Boxtel CJ. Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci. 1999;20:199-205.
23. Cirla A, Mann J. Combrestatins: from natural products to drug discovery. Nat Prod Rep. 2003;20:558-564.
24. Pinney KG, Jelinek C, Edvardsen K, Chaplin DJ, Pettit GR. The discovery and development of the combrestatins. In: Cragg GM, Kingston DGI, Newman DJ, eds. Anticancer Agents from Natural Products. Boca Raton, FL: CRC Press; 2005:23-46.
25. West CML, Price P. Combrestatin A4 phosphate. Anticancer Drugs. 2004;15:179-187.
26. Young SL, Chaplin DJ. Combrestatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs. 2004;13:1171-1182.
27. Powell RG, Weisleder D, Smith CR, Rohwedder WK. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett. 1970;11:815-818.
28. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brian SM. Homoharringtonine: history, current research, and future direction. Cancer. 2001;92:1591-1603.
29. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004;64:3243-3255.
30. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of ingenol 3-angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64:2833-2839.
31. Kamsteeg M, Rutherford T, Sapi E, et al. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresitant ovarian cancer cells. Oncogene. 2003;22:2611-2620.
32. Constantinou AI, Mehta R, Husband A. Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague-Dawley rats. Eur J Cancer. 2003;39:1012-1018.
33. Shibata S, Tanaka O, Sado M, Tsushima S. The genuine sapogenin of ginseng. Tetrahedron Lett. 1963;4:795-800.
34. Jia W, Yan H, Bu X, Liu G, Zhao Y. Aglycone protopanaxadiol, a ginseng saponin, inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells. J Clin Oncol. 2004;22:9663.
35. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res. 2002;8:2666-2674.
36. Fidler JM, Li K, Chung C, et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther. 2003;2:855-862.
37. Sneader W. Drug Discovery: A History. Hoboken, NJ: John Wiley & Sons; 2005.
38. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs. 2004;64:969-982.
39. Frattarelli DAC, Reed MD, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs. 2004;64:949-968.
40. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64:63-88.
41. Chapman TM, Perry CM. Everolimus. Drugs. 2004;64:861-872.
42. Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs. 2002;62:1771-1804.
43. Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther. 2005;27: 1215-1227.
44. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005;80:223-229.
45. Bardsley-Elliot A, Noble S, Foster RH. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation. BioDrugs. 1999;12:363-410.
46. Curran MP, Keating GM. Mycophenolate sodium delayed release: prevention of renal transplant rejection. Drugs. 2005;65: 799-805.
47. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs. 2002;62:2075-2085.
48. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs. 2004;4:117-138.
49. Mukhtar RYA, Reid J, Reckless JPD. Pitavastatin. Int J Clin Pract. 2005;59:239-252.
50. Fenton C, Keating GM, Curran MP. Daptomycin. Drugs. 2004;64:445-455.
51. Ogawa M. Novel anticancer drugs in Japan. J Cancer Res Clin Oncol. 1999;125:134-140.
52. Sugiura T, Ariyoshi Y, Negoro S, et al. Phase I/II study of armubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer. Invest New Drugs. 2005;23:331-337.
53. Perry CM, Ibbotson T. Biapenem. Drugs. 2002;62:2221-2234.
54. Darkes MJM, Plosker GL. Cefditoren pivoxil. Drugs. 2002;62:319-336.
55. Keating G, Figgitt D. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs. 2003;63:2235-2263.
56. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother. 2003;51:513-521.
57. McCormack PL, Perry CM. Caspofungin A: review of its use in the treatment of fungal infections. Drugs. 2005;65:2049-2068.
58. Sader HS, Gales AC. Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents. Drugs. 2001;61:553-564.
59. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003;17:493-503.
60. 1. J Am Chem Soc. 1987;109:3464-3466.
61. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98:2095-2104.
62. Portugal J. Chartreusin, elsamicin A and related anti-cancer antibiotics. Curr Med Chem Anticancer Agents. 2003;3:411-420.
63. Lam KS, Veitch JA, Forenza S, Combs CM, Colson KL. Biosynthesis of elsamicin A, a novel antitumor antibiotic. J Nat Prod. 1989;52:1015-1021.
64. DiMarco A, Gaetani M, Orezzi P, Scotti T, Arcamone FF. Experimental studies on distamycin A - a new antibiotic with cytotoxic activity. Cancer Chemother Rep. 1962;18:15-19.
65. Broggini M, Marchini S, Fontana E, Moneta D, Fowst C, Geroni C. Brostacillin: a new concept in minor groove DNA binder development. Anticancer Drugs. 2004;15:1-6.
66. Geroni C, Marchini S, Cozzi P, et al. Brostalicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res. 2002;62:2332-2336.
67. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo). 1970;23:442-447.
68. Sasaki K, Rinehart KL Jr, Slomp G, Grostic MF, Olson BC. Geldanamycin. I. Structure assignment. J Am Chem Soc. 1970;92:7591-7593.
69. Bisht KS, Bradbury M, Mattson D, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 2003;63:8984-8995.
70. Kaur G, Belotti D, Burger AM, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res. 2004;10:4813-4821.
71. Supko JG, Eder JP, Ryan DP, et al. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res. 2003;9:5178-5186.
72. Yoshinari T, Ohkabo M, Fukasawa K, et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. 1999;59:4271-4275.
73. Zaugg K, Rocha S, Resch H, et al. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res. 2001;61:732-738.
74. Long BH, Rose WC, Vyas DM, Matson JA, Forenza S. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr Med Chem Anticancer Agents. 2002;2:255-266.
75. Chen J, De Angelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101:14479-14484.
76. 473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin Cancer Res. 2004;10:7192-7198.
77. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biological and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669-3676.
78. Marshall JL, Kindler H, Deeken J, et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005;23:31-37.
79. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo). 1976;29:1-6.
80. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2:721-728.
81. Arts J, Schepper S, Emelen K. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem. 2003;10:2343-2350.
82. Atadja P, Gao L, Kwon P, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004;64:689-695.
83. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem. 2005;40:1-13.
84. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipetide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718-728.
85. Shiraga T, Tozuka Z, Ishimura R, Kawamura A, Kagawama A. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005;28:124-129.
86. Kosmidis PA, Manegold C. Advanced NSCLC: new cytostatic agents. Lung Cancer. 2003;41:S123-S132.
87. Starks CM, Zhou Y, Liu F, Licari PJ. Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentation. J Nat Prod. 2003;66:1313-1317.
88. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015-2025.
89. Rizvi N, Villalona-Calere M, Lynch T, et al. Phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. Lung Cancer. 2005;49:S266-S267.
90. Chun E, Han CY, Yoon JH, Sim TB, Kim Y-K, Lee K-Y. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer. 2005;114:124-130.
91. Bernier SG, Lazarus DD, Clark E, et al. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA. 2004;101:10768-10773.
92. McMorris TC, Anchel M. Fungal metabolites. The structures of the novel sesquiterpenoids illudin-S and -M. J Am Chem Soc. 1965;87:1594-1600.
93. McMorris TC, Kelner MJ, Wang W, Yu J, Estes LA, Taetle R. (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. J Nat Prod. 1996;59:896-899.
94. Wang J, Wiltshire T, Wang Y, et al. ATM-dependent CHK2 activation induced by anticancer agent, irfulven. J Biol Chem. 2004;279:39584-39592.
95. Newman DJ, Cragg GM. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr Med Chem. 2004;11:1693-1713.
96. Newman DJ, Cragg GM. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod. 2004;67:1216-1238.
97. Capon RJ. Marine bioprospecting-trawling for treasure and pleasure. Eur J Org Chem. 2001;2001:633-645.
98. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today. 2003;8:536-544.
99. Jensen PR, Fenical W. Marine microorganisms and drug discovery: current status and future potential. In: Fusetani N, ed. Drugs from the Sea. New York: Karger; 2000:6-29.
100. Schroeder CI, Smythe ML, Lewis RJ. Development of small molecules that mimic the binding of ω-conotoxins at the N-type voltage-gated calcium channel. Mol Divers. 2004;8:127-134.
101. Taraboletti G, Poli M, Dossi R, et al. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer. 2004;90:2418-2424.
102. Natori T, Morita M, Akimoto K, Koezuka Y. Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus. Tetrahedron. 1994;50:2771-2784.
103. Hayakawa Y, Rovero S, Forni G, Smyth MJ. α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA. 2003;100:9464-9469.
104. Newman DJ. The bryostatins. In: Cragg GM, Kingston DGI, Newman DJ, eds. Anticancer Agents from Natural Products. Boca Raton, FL: CRC Press; 2005:137-150.
105. Honore S, Kamath K, Braguer D, Wilson L, Briand C, Jordan MA. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol Cancer Ther. 2003;2:1303-1311.
106. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc. 1987;109:6883-6885.
107. Pettit GR, Kamano Y, Dufresne C, Cerny RL, Herald CL, Schmidt JM. Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J Am Chem Soc. 1989;54:6005-6006.
108. Kerbrat P, Dieras V, Pavlidis N, Ravaud A, Wanders J, Fumoleau P. Phase II study LU103793 (dolastatin analogue) in patients with metastatic breast cancer. Eur J Cancer. 2003;39:317-320.
109. Marks RS, Graham DL, Sloan JA, et al. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced nonsmall-cell lung cancer. Am J Clin Oncol. 2003;26:336-337.
110. Kindler HL, Tothy PK, Wolff R, et al. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005;23:489-493.
111. Perez EA, Hillman DW, Fishkin PA, et al. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005;23:257-261.
112. Jordan MA, Kamath K, Manna T, et al. The primary antimiotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086-1095.
113. Loganzo F, Hari M, Annable T, et al. Cells resistant to HT-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin. Mol Cancer Ther. 2004;3:1319-1327.
114. Suárez Y, González L, Cuadrado A, Berciano M, Lafarga M, Muñoz A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther. 2003; 2:863-872.
115. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FAE, Giaccone G. Kahalalide F induces necrosis-like cell death that involves depletion of ErB3 and inhibition of Akt signaling. Mol Pharmacol. 2005;68:502-510.
116. Jimeno JM, Garcia-Gravalos D, Avila J, Smith B, Grant W, Faircloth GT. ES-285, a marine natural product with activity against solid tumors. Clin Cancer Res. 1999;5:3792s.
117. Cuadros R, Garcini EM, Wandosell F, Faircloth G, Fernández-Sousa JM, Avila J. The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett. 2000;152:23-29.
118. Moore KS, Wehrli S, Roger H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA. 1993;90:1354-1358.
119. Hao D, Hammond LA, Eckhardt SG, et al. A phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. Clin Cancer Res. 2003;9:2465-2471.
120. Soares DG, Poletto NP, Bonatto D, Salvador M, Schwartsmann G, Henriques JAP. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol. 2005;70:59-69.
121. Rinehart KL. Antitumor compounds from tunicates. Med Res Rev. 2000;20:1-27.
122. Chen X, Chen J, De Paolis M, Zhu J. Synthetic studies toward ecteinascidin 743. J Org Chem. 2005;70:4397-4408.
123. Malhotra R, Singh L, Eng J, Raufman J-P. Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regul Pept. 1992;41:149-156.
124. Keating GM. Exenatide. Drugs. 2005;65:1681-1692.
125. Gladwell TD. Bivalirudin: A direct thrombin inhibitor. Clin Ther. 2002;24:38-58.
126. Ledizet M, Harrison LM, Koskia RA, Cappello M. Discovery and preclinical development of antithrombotics from hematophagous invertebrates. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:1-10.